Author

P. Probst

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

D. Neri· 2 shared M. Stringhini· 2 shared A. Villa· 1 shared B. Gouyou· 1 shared C. Hutmacher· 1 shared E. Puca· 1 shared G. Pellegrini· 1 shared M. Matasci· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

D. Neri

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Immunotherapy of CT26 murine tumors is characterized by an oligoclonal response against the AH1 tumor rejection antigen

P. Probst, M. Stringhini, D. Neri

This study shows that immunotherapy of CT26 tumors using cytokine-based treatments leads to an oligoclonal T cell response targeting the AH1 antigen.

bioRxiv · Oct 2, 2019Immunology

The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune check-point inhibitors

E. Puca, P. Probst, M. Stringhini, P. Murer, G. Pellegrini, S. Cazzamalli, C. Hutmacher, B. Gouyou, S. Wulhfard, M. Matasci, A. Villa, D. Neri

This paper describes a fusion protein that delivers interleukin-12 to tumors, enhancing NK and CD8+ T cell activity and synergizing with checkpoint inhibitors.

bioRxiv · Jul 3, 2019Cancer Biology